Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) is projected to post its Q1 2025 quarterly earnings results before the market opens on Tuesday, May 6th. Analysts expect Vigil Neuroscience to post earnings of ($0.53) per share for the quarter.
Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.08). On average, analysts expect Vigil Neuroscience to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Vigil Neuroscience Stock Performance
NASDAQ:VIGL traded up $0.19 during trading hours on Friday, reaching $2.75. The stock had a trading volume of 414,325 shares, compared to its average volume of 481,170. Vigil Neuroscience has a 12-month low of $1.31 and a 12-month high of $6.06. The stock has a 50 day simple moving average of $1.92 and a 200 day simple moving average of $2.36. The stock has a market cap of $135.09 million, a P/E ratio of -1.33 and a beta of 1.94.
Analyst Upgrades and Downgrades
VIGL has been the subject of a number of research reports. Guggenheim reiterated a "buy" rating on shares of Vigil Neuroscience in a research report on Friday, January 24th. Wedbush cut their price objective on shares of Vigil Neuroscience from $24.00 to $13.00 and set an "outperform" rating for the company in a report on Friday, March 14th. HC Wainwright lowered their target price on shares of Vigil Neuroscience from $17.00 to $14.00 and set a "buy" rating on the stock in a report on Friday, March 14th. Finally, William Blair raised Vigil Neuroscience to a "strong-buy" rating in a report on Thursday, April 24th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $16.25.
View Our Latest Analysis on Vigil Neuroscience
Vigil Neuroscience Company Profile
(
Get Free Report)
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Further Reading
Before you consider Vigil Neuroscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vigil Neuroscience wasn't on the list.
While Vigil Neuroscience currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
